研究者業績
基本情報
- 所属
- 藤田医科大学 医療科学部/大学院医療科学研究科 研究推進ユニット レギュラトリーサイエンス分野 ユニット長, 分野教授(兼任)精神・神経病態解明センター 神経化学部門 部門長
- 学位
- 博士(医学)(名古屋大学大学院医学系研究科)
- J-GLOBAL ID
- 201001019721259872
- researchmap会員ID
- 6000026156
- 外部リンク
経歴
8-
2024年4月 - 現在
-
2022年4月 - 現在
-
2017年4月 - 2022年3月
-
2016年4月 - 2017年4月
-
2012年4月 - 2016年3月
学歴
3-
2003年4月 - 2007年3月
-
2001年4月 - 2003年3月
-
1997年4月 - 2001年3月
受賞
7-
2017年10月
-
2011年10月
-
2011年8月
論文
159-
Neuroscience 603 239-251 2026年5月25日Animal models are essential for studying aversive states such as fear and pain. Facial expressions may provide non-invasive readouts of aversive states in animals. This study investigated whether changes in facial expressions, which are potentially consistent between humans and mice, can serve as objective indicators of fear responses and distinguish fear from pain. We analyzed changes in the facial expressions of mice associated with conditioned fear stress (CFS) using convolutional neural networks (CNNs). Photographs of CFS and control mice were analyzed using four advanced CNN models: VGG16, ResNet50, DenseNet121, and InceptionV3. The CNNs identified CFS mice from facial images under contrasts: control/non-freezing vs CFS/freezing and control/non-freezing vs CFS/non-freezing, with consistently high performance (Control/non-freezing vs CFS/freezing: sensitivity 0.942, specificity 0.929, accuracy 0.935, precision 0.929, AUC 0.966; Control/non-freezing vs CFS/non-freezing: sensitivity 0.912, specificity 0.900, accuracy 0.906, precision 0.902, AUC 0.950). The ability to detect CFS without freezing decreased as stress intensity weakened, from an AUC of 0.950 to 0.701, suggesting that CNNs can detect facial changes depending on the degree of stress exposure. Facial changes were particularly pronounced in freezing mice, further supporting their association with CFS-related emotional responses. During testing, mice were returned to the conditioning chamber without shock; therefore, this facial expression could reflect fear response rather than pain response. These findings demonstrate the potential of CNNs to serve as non-invasive tools for detecting stress-induced affective changes in mice.
-
Neurochemistry international 197 106184-106184 2026年5月14日High salt (HS) intake is a major risk factor of hypertension and has been implicated in emotional and cognitive decline. On the other hand, dietary supplementation may represent a potential preventive strategy against health risks induced by HS intake. Soybean lecithin is widely used as a phospholipid supplement. Here, we investigated the effects of lysolecithin enriched in lysophosphatidylcholine (>70% of total phospholipids; LPC70) on hypertension and behavioral impairments under high-salt diet (HSD) conditions in mice. To further characterize these effects, we examined changes in prostaglandin (PG)-related pathways by integrating gene expression and lipidomic analyses. Mice were fed an HSD (chow containing 8% NaCl) with or without LPC70 for 10 weeks. HSD elevated systolic blood pressure and impaired social behavior and object recognition memory in mice. Quantitative gene expression analyses revealed that HSD increased renal expression of cyclooxygenase-2 (COX-2) and EP3 (PGE2 receptor), and reduced expression of DP1 (PGD2 receptor) in the prefrontal cortex. LPC70 attenuated these changes in behavior, blood pressure, and PG-related gene expression. Furthermore, lipidomic analyses revealed that HSD reduced circulating arachidonic acid (AA) levels, whereas LPC70 increased AA-derived PG, such as PGE2 and PGD2, in HSD-fed mice. These findings demonstrate that LPC70 may protect against hypertension and behavioral impairments under HSD conditions in mice, potentially in association with modulation of PG signaling. LPC70 may serve as a functional dietary component that reshapes lipid mediator signaling under HSD conditions.
-
Neurochemistry international 195 106141-106141 2026年5月Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS). Although activation of the kynurenine (KYN) pathway has been observed in patients with MS, its pathological significance remains unclear. In this study, we investigated the role of the KYN pathway in MS using an experimental autoimmune encephalomyelitis (EAE) mouse model, a widely recognized animal model of MS. We found an increase in the expression of kynureninase (KYNU), a key enzyme in the KYN pathway that is specifically localized within monocytes in the spinal cord of EAE mice. This was accompanied by a significant accumulation of quinolinic acid (QUIN) in the spinal cord. Importantly, similar increases in KYNU expression and QUIN levels were observed in the spinal cord of proteolipid protein overexpressing mice (PLP-tg mice), another model of demyelination. Notably, KYNU knockout (KO) reduced EAE severity and monocyte recruitment to the spinal cord of EAE model mice. These findings suggest that the increase in KYNU expression and the subsequent accumulation of QUIN may contribute to the exacerbation of MS. Taken together, our results indicate that KYNU could be a novel therapeutic target for MS.
-
Trials 27(1) 2026年3月13日BACKGROUND: Although the number of frozen-thawed blastocysts transfer is increasing worldwide, the live birth rate following blastocyst transfer using assisted reproductive technology remains at 30-60%. Thus, improving the pregnancy rate per transfer is an urgent issue. In a previous retrospective study, we evaluated the use of granulocyte-macrophage colony-stimulating factor (GM-CSF)-containing medium for recovery culture to improve the outcomes of frozen-thawed blastocyst transfers. The results demonstrated that the live birth rates increased by approximately 10% following recovery culture in the GM-CSF-containing culture medium. This study aims to prospectively evaluate whether GM-CSF-containing blastocyst recovery culture following thawing increases live birth. METHODS: This is a multicenter, randomized, parallel-group, active-controlled, single-blind trial. The recruitment target is 750 participants meeting the criteria. Enrolled patients are randomized 1:1 to the GM-CSF-containing culture medium group (test group) or the non-GM-CSF-containing culture medium group (control group). The blastocyst recovery culture after warming was defined as an intervention in this study; frozen-thawed blastocysts will be cultured for 3-7 h in GM-CSF-containing medium (test group) or medium without GM-CSF (control group) followed by blastocyst transfer. The primary outcome will be live birth. We will also evaluate embryo transfer outcomes as secondary efficacy endpoints and evaluate perinatal and neonatal outcomes as a safety endpoint. DISCUSSION: This is the first large-scale prospective study to investigate the efficacy of a GM-CSF-containing medium for frozen-thawed blastocyst transfer. The study findings will provide evidence regarding the efficiency of GM-CSF-containing medium for blastocyst recovery culture after warming. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCT1040240159. Registered on January 6, 2025.
-
Movement disorders : official journal of the Movement Disorder Society 2026年2月2日BACKGROUND: Alterations in tryptophan-kynurenine (TRP-KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). OBJECTIVE: The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers. METHODS: A total of 51 patients with MSA and 56 controls were included. CSF TRP metabolites, such as KYN, quinolinic acid (QA), and kynurenic acid (KA), along with neurofilament light chain (NfL), glycoprotein nonmetastatic melanoma protein B (GPNMB), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), were analyzed. RESULTS: Patients with MSA exhibited higher levels of QA, a neuroinflammatory marker, and lower levels of KA, a neuroprotective marker, yielding an elevated QA-to-KA ratio. Neither QA nor KA correlated with clinical scores. GPNMB, sTREM2, and NfL were increased; however, these markers were independent of KYN pathway metabolites. CONCLUSIONS: MSA exhibited a significant imbalance in KYN metabolism, suggesting a shift toward inflammatory processes distinct from classic neuroinflammatory markers. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
MISC
312-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 85-85 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 95-95 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 92-93 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 254-254 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 204-205 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 207-208 2016年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 19 175-176 2016年6月
-
医療薬学 42(2) 69-77 2016年2月がん疼痛患者におけるトラマドールの使用実態調査とその有用性について検討した。がん疼痛に対してトラマドール塩酸塩カプセル(トラマドール)を使用した入院患者、および非オピオイド鎮痛薬開始後にトラマドールが追加使用され、その後、強オピオイドに変更した入院患者(トラマドール追加使用患者:追加使用群)と非オピオイド鎮痛薬からトラマドールを使用せずに強オピオイドを開始した入院患者を対象とした。トラマドール使用した入院患者は143例であった。推奨されているトラマドールの初回投与量は100mg/日であり、推奨用量で開始されていた患者は70.6%であった。痛みの強度や忍容性に応じてトラマドールが追加され、トラマドールでは除痛できない場合には強オピオイドに変更された。トラマドールを開始した患者の約半数が強オピオイドに変更された。トラマドール追加使用群と非追加使用群における強オピオイドに変更時の有害事象の発現率を解析し、追加使用群の悪心・嘔吐の発現率は非追加使用群と比較して有意に低かった。
-
医療薬学 42(2) 69-77 2016年Tramadol is a weak opioid analgesic indicated for the treatment of moderate to severe cancer pain at step 2 of the WHO analgesic ladder. There is little experience of its use in Japan; there are few reported detailed surveys on the usage of tramadol and its usefulness in patients who changed from taking tramadol to taking stronger opioids. The present study included inpatients who took tramadol hydrochloride capsule for cancer pain in the Nagoya University Hospital between October 2011 and March 2014; these patients were retrospectively examined based on electronic medical records. We observed that, out of 143 patients, 101 (71%) were started on a dose of 100 mg/day tramadol. Fortyeight of these 101 patients (48%) were changed to administration of stronger opioids, of which only 4 patients had their tramadol dosages increased to 300 mg/day before being changed to stronger opioids. However, among patients whose administration was changed from tramadol to stronger opioids, the incidences of nausea/vomiting when changing drugs were significantly lower than that among patients who had not taken tramadol (tramadol used group 19.4% vs non-tramadol used group 41.5%: P < 0.05). These results indicate that the incidence of nausea/vomiting may be reduced when changing from taking tramadol to taking stronger opioids after having used tramadol.
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 128(3) S91-S91 2015年7月
-
薬学雑誌 135(3) 507-518 2015年3月薬学部5年生に対する病院実務実習の実技演習プログラムを紹介し、2011・12年度の実習生計119名の確認テストによる知識習得度およびアンケートによる有益性評価について報告した。確認テスト7項目の正答率は、プログラム前に比較してプログラム後で有意に上昇し、救急蘇生法の「気道確保」「胸骨圧迫」や「AED手順」、生体情報モニタの「モニタ表示」に関しては実施前から高く、実施後維持あるいは有意に上昇していた。アンケートでは、80%以上の実習生が実施期間は「ちょうど良い」、各実習項目は「充実していた」と回答し、90%以上が本プログラムは今後の病院/病棟実習や将来の自分の仕事に役立つ、満足しているとしており、実習生にとって非常に有益であったと考えられた。
-
日本医療薬学会年会講演要旨集 25 42-42 2015年
-
日本医療薬学会年会講演要旨集 25 379-379 2015年
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 128-128 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 198-198 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 201-201 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 204-204 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 206-206 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 209-209 2014年11月
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集 24回・44回 211-211 2014年11月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 17 106-106 2014年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 17 73-73 2014年6月
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 17 102-103 2014年6月
書籍等出版物
1共同研究・競争的資金等の研究課題
16-
日本学術振興会 科学研究費助成事業 2025年4月 - 2028年3月
-
科学技術振興機構 戦略的な研究開発の推進 創発的研究支援事業 2022年 - 2028年
-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2020年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2017年4月 - 2022年3月
産業財産権
16メディア報道
5-
夕刊フジプレゼンツ 健活手帖ONLINE https://www.zakzak.co.jp/lif/news/210823/hea2108230001-n1.html 2021年8月 インターネットメディア
-
刑事事件弁護士ナビ 違法薬物で罰せられる薬物四法とは|依存症回復は可能? https://keiji-pro.com/magazine/175/ 2020年11月11日 インターネットメディア
-
ラジオNIKKEI 薬学の時間 http://medical.radionikkei.jp/yakugaku/tag/tag_953.html 2010年3月 テレビ・ラジオ番組